KPV vs Chonluten
Side-by-side comparison of key properties, dosing, and research.
- Summary
- KPV is a naturally occurring anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It powerfully suppresses intestinal and systemic inflammation via melanocortin receptors, making it valuable for IBD, gut healing, and wound repair.
- Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
- Half-Life
- Short half-life (~15–30 minutes), but effects persist longer due to receptor-level anti-inflammatory cascades
- Short (minutes for the peptide); sustained gene-regulatory effects
- Admin Route
- Oral, SubQ, Topical
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 500 mcg – 1 mg
- 10 mg per day
- Frequency
- Once to twice daily
- Daily for 10–30 days
- Key Benefits
- Reduces intestinal inflammation (IBD, Crohn's, colitis)
- Promotes gut mucosal healing and barrier integrity
- Accelerates wound healing topically
- Suppresses systemic inflammatory cytokines
- Antimicrobial properties against pathogens
- Reduces neuroinflammation when administered systemically
- May improve symptoms of inflammatory skin conditions
- Supports bronchial mucosal regeneration and repair
- May improve mucociliary clearance in chronic respiratory conditions
- Anti-inflammatory effects on bronchial epithelium
- Pulmonary anti-aging and tissue preservation
- Supports lung function in COPD and chronic bronchitis
- Well tolerated in combination with other Khavinson bioregulators
- Short tripeptide with efficient cellular penetration
- Side Effects
- Generally very well tolerated
- Mild injection site reactions (SC)
- Rare: transient flushing
- Generally well tolerated
- Mild injection site reactions possible
- No significant adverse pulmonary events reported
- Stacks With
- —
- —